Pfaudler Lecture: Prevention Studies in Alzheimer's Disease

Anton Porsteinsson, M.D. 

Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE).

Alzheimer's disease remains one of the most important medical conditions for which there is no treatment. Among the top ten causes of death, Alzheimer's disease is the onlyone that cannot be prevented, cured, or even slowed. To change this, researchers are conducting clinical trials to find new treatments. These trials need to study large numbers of individuals and follow participants over long periods of time.  TRC-PAD study is short for the Trial-Ready Cohortfor the Prevention of Alzheimer's Dementia. The purpose of the TRC-PAD study is to find many people (also called a cohort) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer's dementia. TRC-PAD will help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible.

The TRC-PAD study is for individuals, age 50 and older, who may be at increased risk for memory loss caused by Alzheimer's disease. To join the TRC-PAD study, you first need to be invited to complete an in-person TRC-PAD visit. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Web study (https://www.aptwebstudy.org/welcome). Members of the Alzheimer Prevention Trials (APT) Web study complete online questionnaires and memory tests. The results of these tests will identify individuals as being eligible for an in-person TRC-PAD visit.